Editorial
Recent improvements in mRNA and immunogenicity
Abdul M. Gbaj
Abstract :
Vaccines avoid many illnesses and save many lives every year. As a result of common vaccine use, the smallpox virus has entirely been eradicated and the occurrence of measles, polio, and other childhood diseases have considerably been abridged around the world. Classical vaccine strategies, for instance, inactivated pathogen, live attenuated, and subunit vaccines, offer strong protection against a diversity of hazardous diseases. In spite of this achievement, there remain chief obstacles to vaccine development against a diversity of infectious pathogens, particularly those better able to avoid the adaptive immune response. Furthermore, for most emerging virus vaccines, the main barrier is not the efficiency of usual approaches but the requirements for more rapid development and large-scale use. Nucleic acid therapeutics have appeared as a hopeful option to classical vaccine approaches. The messenger ribonucleic acid (mRNA) is the intermediate step connecting the translation of protein-encoding DNA and the manufacturing of proteins by ribosomes in the cytoplasm. Global efforts have been taken to develop SARS-CoV-2 vaccines since the initiation of the current COVID-19 pandemic. The mRNA vaccines (i.e., mRNA-1273 and BNT162b2) are the most commonly approved vaccines worldwide which are utilized in different clinical trials on a global scale [1].
References
1. Addeo A, Shah PK, Bordry N, Hudson RD, Albracht B, Di Marco M, Kaklamani V, Dietrich PY, Taylor BS, Simand PF, Patel D, Wang J, Labidi-Galy I, Fertani S, RJ, Sandoval J, Mesa R, Kate Lathrop R, Mach N, Dimpy P Shah DP (2021) Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 39 (8): 1091-1098. doi: 10.1016/j.ccell.2021.06.009
2. Salleh MZ, Norazmi MN, Deris ZZ (2022) Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2. Biochemistry, Biophysics and Molecular Biology section - Peer Journal. 10: e13083. doi: 10.7717/peerj.13083
3. Mehrabi Nejad MM, Moosaie F, Dehghanbanadaki, H, Ghadery AH, Shabani M, Tabary M, Aryannejad A, Seyed Alinaghi SA, Rezaei N (2022) Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: a systematic review and meta-analysis. European Journal of Medical Research. 27: 23. doi: 10.1186/s40001-022-00648-5
Citation :
Gbaj AM (2022) Recent improvements in mRNA and immunogenicity. Mediterr J Pharm Pharm Sci. 2 (2): 1-2. [Article number: 60]. https://doi.org/10.5281/zenodo.6780430